Inflammation and lung carcinogenesis: applying findings in prevention and treatment

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J. Clin.57(1), 43–66 (2007).
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature420(6917), 860–867 (2002).
   PubMed Web of Science ®Google Scholar
• de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer6(1), 24–37 (2006).
   PubMed Web of Science ®Google Scholar
• Smith CJ, Perfetti TA, King JA. Perspectives on pulmonary inflammation and lung cancer risk in cigarette smokers. Inhal. Toxicol.18(9), 667–677 (2006).
   PubMed Web of Science ®Google Scholar
• Brody JS, Spira A. State of the art. Chronic obstructive pulmonary disease, inflammation, and lung cancer. Proc. Am. Thorac. Soc.3(6), 535–537 (2006).
   PubMedGoogle Scholar
• Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology5(2), 138–146 (1994).
   PubMed Web of Science ®Google Scholar
• Moysich KB, Menezes RJ, Ronsani A et al. Regular aspirin use and lung cancer risk. BMC Cancer2, 31 (2002).
   PubMed Web of Science ®Google Scholar
• Katori M, Majima M. Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors. Inflamm. Res.49(8), 367–392 (2000).
   PubMed Web of Science ®Google Scholar
• Herschman HR. Prostaglandin synthase 2. Biochim. Biophys. Acta1299(1), 125–140 (1996).
   PubMed Web of Science ®Google Scholar
• Malkowski MG, Ginell SL, Smith WL, Garavito RM. The productive conformation of arachidonic acid bound to prostaglandin synthase. Science289(5486), 1933–1937 (2000).
   PubMed Web of Science ®Google Scholar
• FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat. Rev. Drug Discov.2(11), 879–890 (2003).
   PubMed Web of Science ®Google Scholar
• Jick SS. The risk of gastrointestinal bleed, myocardial infarction, and newly diagnosed hypertension in users of meloxicam, diclofenac, naproxen, and piroxicam. Pharmacotherapy20(7), 741–744 (2000).
   PubMed Web of Science ®Google Scholar
• Vane JR. Biomedicine. Back to an aspirin a day? Science296(5567), 474–475 (2002).
   PubMed Web of Science ®Google Scholar
• Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest.116(1), 4–15 (2006).
   PubMed Web of Science ®Google Scholar
• Huang M, Stolina M, Sharma S et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res.58(6), 1208–1216 (1998).
   PubMed Web of Science ®Google Scholar
• Wolff H, Saukkonen K, Anttila S et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res.58(22), 4997–5001 (1998).
   PubMed Web of Science ®Google Scholar
• Hida T, Yatabe Y, Achiwa H et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res.58(17), 3761–3764 (1998).
   PubMed Web of Science ®Google Scholar
• Brabender J, Park J, Metzger R et al. Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Ann. Surg.235(3), 440–443 (2002).
   PubMed Web of Science ®Google Scholar
• Achiwa H, Yatabe Y, Hida T et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin. Cancer Res.5(5), 1001–1005 (1999).
   PubMed Web of Science ®Google Scholar
• Hosomi Y, Yokose T, Hirose Y et al. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer30(2), 73–81 (2000).
   PubMed Web of Science ®Google Scholar
• Kim HS, Youm HR, Lee JS et al. Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer. Lung Cancer42(2), 163–170 (2003).
   PubMed Web of Science ®Google Scholar
• Khuri FR, Wu H, Lee JJ et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin. Cancer Res.7(4), 861–867 (2001).
   PubMed Web of Science ®Google Scholar
• Tsubochi H, Sato N, Hiyama M et al. Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer. Ann. Thorac. Surg.82(4), 1198–1204 (2006).
   PubMed Web of Science ®Google Scholar
• Campa D, Zienolddiny S, Maggini V et al. Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis25(2), 229–235 (2004).
   PubMed Web of Science ®Google Scholar
• Huang M, Sharma S, Mao JT, Dubinett SM. Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J. Immunol.157(12), 5512–5520 (1996).
   PubMed Web of Science ®Google Scholar
• Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell83(3), 493–501 (1995).
   PubMed Web of Science ®Google Scholar
• Krysan K, Merchant FH, Zhu L et al. COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J.18(1), 206–208 (2004).
   PubMed Web of Science ®Google Scholar
• Krysan K, Dalwadi H, Sharma S, Pold M, Dubinett S. Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Cancer Res.64(18), 6359–6362 (2004).
   PubMed Web of Science ®Google Scholar
• Leahy KM, Koki AT, Masferrer JL. Role of cyclooxygenases in angiogenesis. Curr. Med. Chem.7(11), 1163–1170 (2000).
   PubMed Web of Science ®Google Scholar
• Gately S, Li WW. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin. Oncol.31(2 Suppl. 7), 2–11 (2004).
   PubMed Web of Science ®Google Scholar
• Liu VC, Wong LY, Jang T et al. Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-β. J. Immunol.178(5), 2883–2892 (2007).
   PubMed Web of Science ®Google Scholar
• Baratelli F, Lin Y, Zhu L et al. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J. Immunol.175(3), 1483–1490 (2005).
   PubMed Web of Science ®Google Scholar
• Dohadwala M, Luo J, Zhu L et al. Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J. Biol. Chem.276(24), 20809–20812 (2001).
   PubMed Web of Science ®Google Scholar
• Dohadwala M, Batra RK, Luo J et al. Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J. Biol. Chem.277(52), 50828–50833 (2002).
   PubMed Web of Science ®Google Scholar
• Sheng H, Shao J, Washington MK, DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J. Biol. Chem.276(21), 18075–18081 (2001).
   PubMed Web of Science ®Google Scholar
• Riedl K, Krysan K, Pold M et al. Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resist. Updat.7(3), 169–184 (2004).
   PubMed Web of Science ®Google Scholar
• Krysan K, Reckamp KL, Dalwadi H et al. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res.65(14), 6275–6281 (2005).
   PubMed Web of Science ®Google Scholar
• Pai R, Soreghan B, Szabo IL et al. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med.8(3), 289–293 (2002).
   PubMed Web of Science ®Google Scholar
• Krysan K, Reckamp KL, Sharma S, Dubinett SM. The potential and rationale for COX-2 inhibitors in lung cancer. Anticancer Agents Med. Chem.6(3), 209–220 (2006).
   PubMedGoogle Scholar
• Ding Y, Tong M, Liu S, Moscow JA, Tai HH. NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis26(1), 65–72 (2005).
   PubMed Web of Science ®Google Scholar
• Wolf I, O’Kelly J, Rubinek T et al. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res.66(15), 7818–7823 (2006).
   PubMed Web of Science ®Google Scholar
• Cho H, Tai HH. Inhibition of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by cyclooxygenase inhibitors and chemopreventive agents. Prostaglandins Leukot. Essent. Fatty Acids67(6), 461–465 (2002).
   PubMed Web of Science ®Google Scholar
• Hazra S, Batra RK, Tai HH et al. Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Mol. Pharmacol.71(6), 1715–1720 (2007).
   PubMed Web of Science ®Google Scholar
• Han S, Inoue H, Flowers LC, Sidell N. Control of COX-2 gene expression through peroxisome proliferator-activated receptor γ in human cervical cancer cells. Clin. Cancer Res.9(12), 4627–4635 (2003).
   PubMed Web of Science ®Google Scholar
• Subbaramaiah K, Lin DT, Hart JC, Dannenberg AJ. Peroxisome proliferator-activated receptor γ ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. J. Biol. Chem.276(15), 12440–12448 (2001).
   PubMed Web of Science ®Google Scholar
• Li MY, Deng H, Zhao JM, Dai D, Tan XY. PPARγ pathway activation results in apoptosis and COX-2 inhibition in HepG2 cells. World J. Gastroenterol.9(6), 1220–1226 (2003).
   PubMed Web of Science ®Google Scholar
• Berger J, Moller DE. The mechanisms of action of PPARs. Annu. Rev. Med.53, 409–435 (2002).
   PubMed Web of Science ®Google Scholar
• Inoue H, Tanabe T, Umesono K. Feedback control of cyclooxygenase-2 expression through PPARγ. J. Biol. Chem.275(36), 28028–28032 (2000).
   PubMed Web of Science ®Google Scholar
• Rossi A, Kapahi P, Natoli G et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature403(6765), 103–108 (2000).
   PubMed Web of Science ®Google Scholar
• Keshamouni VG, Arenberg DA, Reddy RC et al. PPAR-γ activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer. Neoplasia7(3), 294–301 (2005).
   PubMed Web of Science ®Google Scholar
• Bren-Mattison Y, Van Putten V, Chan D et al. Peroxisome proliferator-activated receptor-γ (PPARγ) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). Oncogene24(8), 1412–1422 (2005).
   PubMed Web of Science ®Google Scholar
• Su CG, Wen X, Bailey ST et al. A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response. J. Clin. Invest.104(4), 383–389 (1999).
   PubMed Web of Science ®Google Scholar
• Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor γ in non-small cell lung cancer. Cancer Res.60(4), 1129–1138 (2000).
   PubMed Web of Science ®Google Scholar
• Han S, Roman J. Peroxisome proliferator-activated receptor γ: a novel target for cancer therapeutics? Anticancer Drugs18(3), 237–244 (2007).
   PubMed Web of Science ®Google Scholar
• Li M, Pascual G, Glass CK. Peroxisome proliferator-activated receptor γ-dependent repression of the inducible nitric oxide synthase gene. Mol. Cell. Biol.20(13), 4699–4707 (2000).
   PubMed Web of Science ®Google Scholar
• Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature391(6662), 79–82 (1998).
   PubMed Web of Science ®Google Scholar
• Weng JR, Chen CY, Pinzone JJ, Ringel MD, Chen CS. Beyond peroxisome proliferator-activated receptor γ signaling: the multi-facets of the antitumor effect of thiazolidinediones. Endocr. Relat. Cancer13(2), 401–413 (2006).
   PubMed Web of Science ®Google Scholar
• Chawla A, Barak Y, Nagy L et al. PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med.7(1), 48–52 (2001).
   PubMed Web of Science ®Google Scholar
• Zou W, Liu X, Yue P, Khuri FR, Sun SY. PPARγ ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells. Cancer Biol. Ther.6(1), 99–106 (2007).
   PubMed Web of Science ®Google Scholar
• Durbin RJ. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes. Metab.6(4), 280–285 (2004).
   PubMed Web of Science ®Google Scholar
• Galli A, Mello T, Ceni E, Surrenti E, Surrenti C. The potential of antidiabetic thiazolidinediones for anticancer therapy. Expert Opin. Investig. Drugs15(9), 1039–1049 (2006).
   PubMed Web of Science ®Google Scholar
• Govindarajan R, Ratnasinghe L, Simmons DL et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J. Clin. Oncol.25(12), 1476–1481 (2007).
   PubMed Web of Science ®Google Scholar
• Ramos-Nino ME, Maclean CD, Littenberg B. Association between cancer prevalence and use of thiazolidinediones (TZDs): results from the Vermont Diabetes Information System. BMC Med.5(1), 17 (2007).
   PubMed Web of Science ®Google Scholar
• Rosen CJ. The rosiglitazone story – lessons from an FDA advisory committee meeting. N. Engl. J. Med.357(9), 844–846 (2007).
   PubMed Web of Science ®Google Scholar
• No authors listed. Thiazolidinediones and cardiovascular disease. Med. Lett. Drugs Ther.49(1265), 57–58 (2007).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med.356(24), 2457–2471 (2007).
   PubMed Web of Science ®Google Scholar
• Stearman RS, Dwyer-Nield L, Zerbe L et al. Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am. J. Pathol.167(6), 1763–1775 (2005).
   PubMed Web of Science ®Google Scholar
• Keith RL, Miller YE, Hudish TM et al. Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice. Cancer Res.64(16), 5897–5904 (2004).
   PubMed Web of Science ®Google Scholar
• Keith RL, Miller YE, Hoshikawa Y et al. Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Res.62(3), 734–740 (2002).
   PubMed Web of Science ®Google Scholar
• Mao JT, Tsu IH, Dubinett SM et al. Modulation of pulmonary leukotriene B4 production by cyclooxygenase-2 inhibitors and lipopolysaccharide. Clin. Cancer Res.10(20), 6872–6878 (2004).
   PubMed Web of Science ®Google Scholar
• Dubois RN, Abramson SB, Crofford L et al. Cyclooxygenase in biology and disease. FASEB J.12(12), 1063–1073 (1998).
   PubMed Web of Science ®Google Scholar
• Breyer RM, Kennedy CR, Zhang Y, Breyer MD. Structure-function analyses of eicosanoid receptors. Physiologic and therapeutic implications. Ann. NY Acad. Sci.905, 221–231 (2000).
   PubMed Web of Science ®Google Scholar
• Yang L, Huang Y, Porta R et al. Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. Cancer Res.66(19), 9665–9672 (2006).
   PubMed Web of Science ®Google Scholar
• Han S, Ritzenthaler JD, Wingerd B, Rivera HN, Roman J. Extracellular matrix fibronectin increases prostaglandin E2 receptor subtype EP4 in lung carcinoma cells through multiple signaling pathways: the role of AP-2. J. Biol. Chem.282(11), 7961–7972 (2007).
   PubMed Web of Science ®Google Scholar
• Sevenoaks MJ, Stockley RA. Chronic obstructive pulmonary disease, inflammation and co-morbidity – a common inflammatory phenotype? Respir. Res.7, 70 (2006).
   PubMed Web of Science ®Google Scholar
• Rennard SI. Chronic obstructive pulmonary disease: linking outcomes and pathobiology of disease modification. Proc. Am. Thorac. Soc.3(3), 276–280 (2006).
   PubMedGoogle Scholar
• O’Donnell R, Breen D, Wilson S, Djukanovic R. Inflammatory cells in the airways in COPD. Thorax61(5), 448–454 (2006).
   PubMed Web of Science ®Google Scholar
• Reynolds PR, Cosio MG, Hoidal JR. Cigarette smoke-induced Egr-1 upregulates proinflammatory cytokines in pulmonary epithelial cells. Am. J. Respir. Cell Mol. Biol.35(3), 314–319 (2006).
   PubMed Web of Science ®Google Scholar
• Tan RJ, Fattman CL, Niehouse LM et al. Matrix metalloproteinases promote inflammation and fibrosis in asbestos-induced lung injury in mice. Am. J. Respir. Cell Mol. Biol.35(3), 289–297 (2006).
   PubMed Web of Science ®Google Scholar
• Soberman RJ, Christmas P. Revisiting prostacyclin: new directions in pulmonary fibrosis and inflammation. Am. J. Physiol. Lung Cell Mol. Physiol.291(2), L142–L143 (2006).
   Google Scholar
• Charuworn B, Dohadwala M, Krysan K et al. Inflammation-mediated promotion of EMT in NSCLC: IL-1β mediates a MEK/Erk- and JNK/SAPK-dependent down-regulation of E-cadherin. In: Proceedings of the American Thoracic Society. Leff A (Ed.). The American Thoracic Society, NY , USA D96 (2006).
   Google Scholar
• Leng Q, Bentwich Z, Borkow G. Increased TGF-β, Cbl-b and CTLA-4 levels and immunosuppression in association with chronic immune activation. Int. Immunol.18(5), 637–644 (2006).
   PubMed Web of Science ®Google Scholar
• Keshamouni VG, Michailidis G, Grasso CS et al. Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype. J. Proteome Res.5(5), 1143–1154 (2006).
   PubMed Web of Science ®Google Scholar
• Dohadwala M, Yang SC, Luo J et al. Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res.66(10), 5338–5345 (2006).
   PubMed Web of Science ®Google Scholar
• Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol.17(5), 548–558 (2005).
   PubMed Web of Science ®Google Scholar
• Dey SK, Chien SM, Cox CL, Crist RD. Prostaglandin synthesis in the rabbit blastocyst. Prostaglandins19(3), 449–453 (1980).
   PubMedGoogle Scholar
• Davis DL, Pakrasi PL, Dey SK. Prostaglandins in swine blastocysts. Biol. Reprod.28(5), 1114–1118 (1983).
   PubMed Web of Science ®Google Scholar
• Cha YI, Kim SH, Sepich D et al. Cyclooxygenase-1-derived PGE2 promotes cell motility via the G-protein-coupled EP4 receptor during vertebrate gastrulation. Genes Dev.20(1), 77–86 (2006).
   PubMed Web of Science ®Google Scholar
• Thiery JP. Epithelial–mesenchymal transitions in development and pathologies. Curr. Opin. Cell Biol.15(6), 740–746 (2003).
   PubMed Web of Science ®Google Scholar
• Dasari V, Gallup M, Lemjabbar H, Maltseva I, McNamara N. Epithelial–mesenchymal transition in lung cancer: is tobacco the “smoking gun”? Am. J. Respir. Cell Mol. Biol.35(1), 3–9 (2006).
   PubMed Web of Science ®Google Scholar
• Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial–mesenchymal transition: new insights in signaling, development, and disease. J. Cell Biol.172(7), 973–981 (2006).
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Adjei AA, Bunn PA Jr et al. Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clin. Cancer Res.12(14 Pt 2), S4365–S4371 (2006).
   Google Scholar
• Lippman SM, Gibson N, Subbaramaiah K, Dannenberg AJ. Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways. Clin. Cancer Res.11(17), 6097–6099 (2005).
   PubMed Web of Science ®Google Scholar
• Siegfried JM, Gubish CT, Rothstein ME, Queiroz De Oliveira PE, Stabile LP. Signaling pathways involved in cyclooxygenase-2 induction by hepatocyte growth factor in non-small cell lung cancer. Mol. Pharmacol.72(3), 769–779 (2007).
   PubMed Web of Science ®Google Scholar
• Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J. Biol. Chem.277(21), 18649–18657 (2002).
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science316(5827), 1039–1043 (2007).
   PubMed Web of Science ®Google Scholar
• Hsu AL, Ching TT, Wang DS et al. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J. Biol. Chem.275(15), 11397–11403 (2000).
   PubMed Web of Science ®Google Scholar
• Liu XH, Yao S, Kirschenbaum A, Levine AC. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res.58(19), 4245–4249 (1998).
   PubMed Web of Science ®Google Scholar
• Sheng H, Shao J, Morrow J, Beauchamp R, DuBois R. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res.58, 362–366 (1998).
   PubMed Web of Science ®Google Scholar
• Tsujii M, Dubois R. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell83, 493–501 (1995).
   PubMed Web of Science ®Google Scholar
• Lin MT, Lee RC, Yang PC, Ho FM, Kuo ML. Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J. Biol. Chem.276(52), 48997–49002 (2001).
   PubMed Web of Science ®Google Scholar
• Chang YW, Jakobi R, McGinty A et al. Cyclooxygenase 2 promotes cell survival by stimulation of dynein light chain expression and inhibition of neuronal nitric oxide synthase activity. Mol. Cell. Biol.20(22), 8571–8579 (2000).
   PubMed Web of Science ®Google Scholar
• Erickson BA, Longo WE, Panesar N, Mazuski JE, Kaminski DL. The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis. J. Surg. Res.81(1), 101–107 (1999).
   PubMed Web of Science ®Google Scholar
• Hara A, Yoshimi N, Niwa M, Ino N, Mori H. Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines. Jpn. J. Cancer Res.88(6), 600–604 (1997).
   PubMedGoogle Scholar
• Sawaoka H, Kawano S, Tsuji S et al. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am. J. Physiol.274(6 Pt 1), G1061–G1067 (1998).
   PubMed Web of Science ®Google Scholar
• Chang HC, Weng CF. Cyclooxygenase-2 level and culture conditions influence NS398-induced apoptosis and caspase activation in lung cancer cells. Oncol. Rep.8(6), 1321–1325 (2001).
   PubMed Web of Science ®Google Scholar
• Hida T, Kozaki K, Muramatsu H et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin. Cancer Res.6(5), 2006–2011 (2000).
   PubMed Web of Science ®Google Scholar
• Yao R, Rioux N, Castonguay A, You M. Inhibition of COX-2 and induction of apoptosis: two determinants of nonsteroidal anti-inflammatory drugs’ chemopreventive efficacies in mouse lung tumorigenesis. Exp. Lung Res.26(8), 731–742 (2000).
   PubMed Web of Science ®Google Scholar
• Gadgeel SM, Ruckdeschel JC, Heath EI et al. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC). J. Thorac. Oncol.2(4), 299–305 (2007).
   PubMed Web of Science ®Google Scholar
• O’Byrne KJ, Danson S, Dunlop D et al. Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer. J. Clin. Oncol.25(22), 3266–3273 (2007).
   PubMed Web of Science ®Google Scholar
• Reckamp KL, Krysan K, Morrow JD et al. A Phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin. Cancer Res.12(11 Pt 1), 3381–3388 (2006).
   PubMed Web of Science ®Google Scholar
• Witta SE, Gemmill RM, Hirsch FR et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res.66(2), 944–950 (2006).
   PubMed Web of Science ®Google Scholar
• Garber K. HDAC inhibitors overcome first hurdle. Nat. Biotechnol.25(1), 17–19 (2007).
   PubMed Web of Science ®Google Scholar
• Hogan BL. Bone morphogenetic proteins in development. Curr. Opin. Genet. Dev.6(4), 432–438 (1996).
   PubMed Web of Science ®Google Scholar
• Okada H, Kalluri R. Recapitulation of kidney development paradigms by BMP-7 reverses chronic renal injury. Clin. Exp. Nephrol.9(2), 100–101 (2005).
   PubMedGoogle Scholar
• Kopp JB. BMP-7 and the proximal tubule. Kidney Int.61(1), 351–352 (2002).
   PubMed Web of Science ®Google Scholar
• Shi W, Zhao J, Anderson KD, Warburton D. Gremlin negatively modulates BMP-4 induction of embryonic mouse lung branching morphogenesis. Am. J. Physiol. Lung Cell Mol. Physiol.280(5), L1030–L1039 (2001).
   PubMed Web of Science ®Google Scholar
• Bellusci S, Henderson R, Winnier G, Oikawa T, Hogan BL. Evidence from normal expression and targeted misexpression that bone morphogenetic protein (Bmp-4) plays a role in mouse embryonic lung morphogenesis. Development122(6), 1693–1702 (1996).
   PubMed Web of Science ®Google Scholar
• Zeisberg M, Hanai J, Sugimoto H et al. BMP-7 counteracts TGF-β1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat. Med.9(7), 964–968 (2003).
   PubMed Web of Science ®Google Scholar
• Zeisberg M, Yang C, Martino M et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J. Biol. Chem.282(32), 23337–23347(2007).
   PubMed Web of Science ®Google Scholar
• Langenfeld EM, Bojnowski J, Perone J, Langenfeld J. Expression of bone morphogenetic proteins in human lung carcinomas. Ann. Thorac. Surg.80(3), 1028–1032 (2005).
   PubMed Web of Science ®Google Scholar
• Dubinett S, Sharma S, Huang M, Mao JT, Batra R. Cancer and immune dysfunction. In: Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can be Done. Finke J, Bukowski R (Eds). Human Press Inc., NJ, USA 335 (2004).
   Google Scholar
• Sogn JA. Tumor immunology: the glass is half full. Immunity9(6), 757–763 (1998).
   PubMed Web of Science ®Google Scholar
• Yoshino I, Yano T, Murata M et al. Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor. Cancer Res.52(4), 775–781 (1992).
   PubMed Web of Science ®Google Scholar
• Batra RK, Lin Y, Sharma S et al. Non-small cell lung cancer-derived soluble mediators enhance apoptosis in activated T lymphocytes through an I κ B kinase-dependent mechanism. Cancer Res.63(3), 642–646 (2003).
   PubMed Web of Science ®Google Scholar
• Redente EF, Orlicky DJ, Bouchard RJ, Malkinson AM. Tumor signaling to the bone marrow changes the phenotype of monocytes and pulmonary macrophages during urethane-induced primary lung tumorigenesis in A/J mice. Am. J. Pathol.170(2), 693–708 (2007).
   PubMed Web of Science ®Google Scholar
• Huang M, Wang J, Lee P et al. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res.55(17), 3847–3853 (1995).
   PubMed Web of Science ®Google Scholar
• Neuner A, Schindel M, Wildenberg U et al. Cytokine secretion: clinical relevance of immunosuppression in non-small cell lung cancer. Lung Cancer34(Suppl. 2), S79–S82 (2001).
   PubMed Web of Science ®Google Scholar
• Alleva DG, Burger CJ, Elgert KD. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-α production: role of tumor-derived IL-10, TGF-β and prostaglandin E2. J. Immunol.153(4), 1674–1686 (1994).
   PubMed Web of Science ®Google Scholar
• Stolina M, Sharma S, Lin Y et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol.164(1), 361–370 (2000).
   PubMed Web of Science ®Google Scholar
• Wu C-Y, Demeure C, Kiniwa M, Gately M, Delespesse G. IL-12 induces the production of IFN-γ by neonatal human CD4 T cells. J. Immunol.151(4), 1938–1949 (1993).
   PubMed Web of Science ®Google Scholar
• D’Andrea A, Aste-Amezaga M, Valiante NM et al. Interleukin 10 (IL-10) inhibits human lymphocyte interferon γ-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J. Exp. Med.178(3), 1041–1048 (1993).
   PubMed Web of Science ®Google Scholar
• Hagenbaugh A, Sharma S, Dubinett S et al. Altered immune responses in IL-10 transgenic mice. J. Exp. Med.185(12), 2101–2110 (1997).
   Google Scholar
• Halak BK, Maguire HC Jr, Lattime EC. Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res.59(4), 911–917 (1999).
   PubMed Web of Science ®Google Scholar
• Kim J, Modlin RL, Moy RL et al. IL-10 production in cutaneous basal and squamous cell carcinomas: a mechanism for evading the local T cell immune response. J. Immunol.155(4), 2240–2247 (1995).
   PubMed Web of Science ®Google Scholar
• Sharma S, Stolina M, Lin Y et al. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J. Immunol.163(9), 5020–5028 (1999).
   PubMed Web of Science ®Google Scholar
• Hatanaka H, Abe Y, Naruke M et al. Significant correlation between interleukin 10 expression and vascularization through angiopoietin/TIE2 networks in non-small cell lung cancer. Clin. Cancer Res.7(5), 1287–1292 (2001).
   PubMed Web of Science ®Google Scholar
• Hatanaka H, Abe Y, Kamiya T et al. Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer. Ann. Oncol.11(7), 815–819 (2000).
   PubMed Web of Science ®Google Scholar
• De Vita F, Orditura M, Galizia G et al. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest117(2), 365–373 (2000).
   PubMed Web of Science ®Google Scholar
• Naruke M, Abe Y, Hatanaka H et al. Interleukin-10 expression is correlated with growth fraction in human non-small cell lung cancer xenografts. Int. J. Oncol.18(6), 1213–1217 (2001).
   PubMed Web of Science ®Google Scholar
• Colombo M, Vagliani M, Spreafico F et al. Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res.56(11), 2531–2534 (1996).
   PubMed Web of Science ®Google Scholar
• Molina-Holgado E, Arevalo-Martin A, Ortiz S, Vela JM, Guaza C. Theiler’s virus infection induces the expression of cyclooxygenase-2 in murine astrocytes: inhibition by the anti-inflammatory cytokines interleukin-4 and interleukin-10. Neurosci. Lett.324(3), 237–241 (2002).
   PubMed Web of Science ®Google Scholar
• Bianchi R, Grohmann U, Belladonna M et al. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells. J. Immunol.157(4), 1589–1597 (1996).
   PubMed Web of Science ®Google Scholar
• Handel-Fernandez ME, Cheng X, Herbert LM, Lopez DM. Down-regulation of IL-12, not a shift from a T helper-1 to a T helper-2 phenotype, is responsible for impaired IFN-γ production in mammary tumor-bearing mice. J. Immunol.158(1), 280–286 (1997).
   PubMed Web of Science ®Google Scholar
• Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol.19, 683–765 (2001).
   PubMed Web of Science ®Google Scholar
• Pomini F, Caruso A, Challis JR. Interleukin-10 modifies the effects of interleukin-1β and tumor necrosis factor-α on the activity and expression of prostaglandin H synthase-2 and the NAD+-dependent 15-hydroxyprostaglandin dehydrogenase in cultured term human villous trophoblast and chorion trophoblast cells. J. Clin. Endocrinol. Metab.84(12), 4645–4651 (1999).
   PubMed Web of Science ®Google Scholar
• Heuze-Vourc’h N, Zhu L, Krysan K et al. Abnormal interleukin 10Rα expression contributes to the maintenance of elevated cyclooxygenase-2 in non-small cell lung cancer cells. Cancer Res.63(4), 766–770 (2003).
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature392(6673), 245–252 (1998).
   PubMed Web of Science ®Google Scholar
• Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu. Rev. Immunol.23, 975–1028 (2005).
   PubMed Web of Science ®Google Scholar
• Yang L, Yamagata N, Yadav R et al. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J. Clin. Invest.111(5), 727–735 (2003).
   PubMed Web of Science ®Google Scholar
• Sharma S, Stolina M, Yang SC et al. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin. Cancer Res.9(3), 961–968 (2003).
   PubMed Web of Science ®Google Scholar
• Serafini P, De Santo C, Marigo I et al. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol. Immunother.53(2), 64–72 (2004).
   PubMed Web of Science ®Google Scholar
• Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol.16(1), 53–65 (2006).
   PubMed Web of Science ®Google Scholar
• Rodriguez PC, Hernandez CP, Quiceno D et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J. Exp. Med.202(7), 931–939 (2005).
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat. Immunol.6(4), 331–337 (2005).
   PubMed Web of Science ®Google Scholar
• Lee JM, Dubinett SM, Sharma S. Immunologic approaches to lung cancer therapy. In: Lung Cancer. Roth J (Ed.). Blackwell Publishers Inc., MA, USA (2005).
   Google Scholar
• Sharma S, Yang SC, Zhu L et al. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res.65(12), 5211–5220 (2005).
   PubMed Web of Science ®Google Scholar
• Papiernik M, de Moraes ML, Pontoux C, Vasseur F, Penit C. Regulatory CD4 T cells: expression of IL-2R α chain, resistance to clonal deletion and IL-2 dependency. Int. Immunol.10(4), 371–378 (1998).
   PubMed Web of Science ®Google Scholar
• Nomura T, Sakaguchi S. Foxp3 and Aire in thymus-generated Treg cells: a link in self-tolerance. Nat. Immunol.8(4), 333–334 (2007).
   PubMed Web of Science ®Google Scholar
• Jordan MS, Boesteanu A, Reed AJ et al. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat. Immunol.2(4), 301–306 (2001).
   PubMed Web of Science ®Google Scholar
• Shevach EM. Regulatory T cells in autoimmmunity. Annu. Rev. Immunol.18, 423–449 (2000).
   PubMed Web of Science ®Google Scholar
• Sakaguchi S. The origin of FOXP3-expressing CD4+ regulatory T cells: thymus or periphery. J. Clin. Invest.112(9), 1310–1312 (2003).
   PubMed Web of Science ®Google Scholar
• Walker MR, Kasprowicz DJ, Gersuk VH et al. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J. Clin. Invest.112(9), 1437–1443 (2003).
   PubMed Web of Science ®Google Scholar
• Gavin MA, Rasmussen JP, Fontenot JD et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature445(7129), 771–775 (2007).
   PubMed Web of Science ®Google Scholar
• Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol.7(1), 41–51 (2007).
   PubMed Web of Science ®Google Scholar
• Yu H, Jove R. The STATs of cancer – new molecular targets come of age. Nat. Rev. Cancer4(2), 97–105 (2004).
   PubMed Web of Science ®Google Scholar
• Murray PJ. The JAK-STAT signaling pathway: input and output integration. J. Immunol.178(5), 2623–2629 (2007).
   PubMed Web of Science ®Google Scholar
• Zhong Z, Wen Z, Darnell JE Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science264(5155), 95–98 (1994).
   PubMed Web of Science ®Google Scholar
• Yu CL, Meyer DJ, Campbell GS et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science269(5220), 81–83 (1995).
   PubMed Web of Science ®Google Scholar
• Odajima J, Matsumura I, Sonoyama J et al. Full oncogenic activities of v-Src are mediated by multiple signaling pathways. Ras as an essential mediator for cell survival. J. Biol. Chem.275(31), 24096–24105 (2000).
   PubMed Web of Science ®Google Scholar
• Turkson J, Bowman T, Garcia R et al. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell. Biol.18(5), 2545–2552 (1998).
   PubMed Web of Science ®Google Scholar
• Song L, Turkson J, Karras JG, Jove R, Haura EB. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene22(27), 4150–4165 (2003).
   PubMed Web of Science ®Google Scholar
• Niu G, Wright KL, Huang M et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene21(13), 2000–2008 (2002).
   PubMed Web of Science ®Google Scholar
• Wei D, Le X, Zheng L et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene22(3), 319–329 (2003).
   PubMed Web of Science ®Google Scholar
• Bromberg JF, Wrzeszczynska MH, Devgan G et al. Stat3 as an oncogene. Cell98(3), 295–303 (1999).
   PubMed Web of Science ®Google Scholar
• Kortylewski M, Kujawski M, Wang T et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med.11(12), 1314–1321 (2005).
   PubMed Web of Science ®Google Scholar
• Niu G, Heller R, Catlett-Falcone R et al. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res.59(20), 5059–5063 (1999).
   PubMed Web of Science ®Google Scholar
• Turkson J, Zhang S, Palmer J et al. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol. Cancer Ther.3(12), 1533–1542 (2004).
   PubMed Web of Science ®Google Scholar
• Haura EB, Livingston S, Coppola D. Autocrine interleukin-6/interleukin-6 receptor stimulation in non-small-cell lung cancer. Clin. Lung Cancer7(4), 273–275 (2006).
   PubMed Web of Science ®Google Scholar
• Yanagawa H, Sone S, Takahashi Y et al. Serum levels of interleukin 6 in patients with lung cancer. Br. J. Cancer71(5), 1095–1098 (1995).
   PubMed Web of Science ®Google Scholar
• Dalwadi H, Krysan K, Heuze-Vourc’h N et al. Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer. Clin. Cancer Res.11(21), 7674–7682 (2005).
   PubMed Web of Science ®Google Scholar
• Turkson J, Ryan D, Kim JS et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J. Biol. Chem.276(48), 45443–45455 (2001).
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Lukyanov AN. Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov. Today8(6), 259–266 (2003).
   PubMed Web of Science ®Google Scholar
• Turkson J, Kim JS, Zhang S et al. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol. Cancer Ther.3(3), 261–269 (2004).
   PubMed Web of Science ®Google Scholar
• Siddiquee K, Zhang S, Guida WC et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc. Natl Acad. Sci. USA104(18), 7391–7396 (2007).
   PubMed Web of Science ®Google Scholar
• Gunning PT, Katt WP, Glenn M et al. Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: structural recognition of STAT SH2 domains. Bioorg. Med. Chem. Lett.17(7), 1875–1878 (2007).
   PubMed Web of Science ®Google Scholar
• Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene19(21), 2468–2473 (2000).
   PubMed Web of Science ®Google Scholar
• Turkson J, Zhang S, Mora LB et al. A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J. Biol. Chem.280(38), 32979–32988 (2005).
   PubMed Web of Science ®Google Scholar
• Sanchez-Ceja SG, Reyes-Maldonado E, Vazquez-Manriquez ME et al. Differential expression of STAT5 and Bcl-xL, and high expression of Neu and STAT3 in non-small-cell lung carcinoma. Lung Cancer54(2), 163–168 (2006).
   PubMed Web of Science ®Google Scholar
• Alvarez JV, Greulich H, Sellers WR, Meyerson M, Frank DA. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res.66(6), 3162–3168 (2006).
   PubMed Web of Science ®Google Scholar
• Nunes M, Shi C, Greenberger LM. Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumor cells and normal human keratinocytes. Mol. Cancer Ther.3(1), 21–27 (2004).
   PubMed Web of Science ®Google Scholar
• Cui X, Yang SC, Sharma S, Heuze-Vourc’h N, Dubinett SM. IL-4 regulates COX-2 and PGE2 production in human non-small cell lung cancer. Biochem. Biophys. Res. Commun.343(4), 995–1001 (2006).
   PubMed Web of Science ®Google Scholar
• Cui X, Zhang L, Luo J et al. Unphosphorylated STAT6 contributes to constitutive cyclooxygenase-2 expression in human non-small cell lung cancer. Oncogene26(29), 4253–4260 (2007).
   PubMed Web of Science ®Google Scholar
• Karin M. Nuclear factor-κB in cancer development and progression. Nature441(7092), 431–436 (2006).
   PubMed Web of Science ®Google Scholar
• Tang X, Liu D, Shishodia S et al. Nuclear factor-κB (NF-κB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer107(11), 2637–2646 (2006).
   PubMed Web of Science ®Google Scholar
• Aggarwal BB. Nuclear factor-κB: the enemy within. Cancer Cell6(3), 203–208 (2004).
   PubMed Web of Science ®Google Scholar
• Luo JL, Kamata H, Karin M. IKK/NF-κB signaling: balancing life and death – a new approach to cancer therapy. J. Clin. Invest.115(10), 2625–2632 (2005).
   PubMed Web of Science ®Google Scholar
• Bharti AC, Aggarwal BB. Nuclear factor-κ B and cancer: its role in prevention and therapy. Biochem. Pharmacol.64(5–6), 883–888 (2002).
   PubMed Web of Science ®Google Scholar
• Ballaz S, Mulshine JL. The potential contributions of chronic inflammation to lung carcinogenesis. Clin. Lung Cancer5(1), 46–62 (2003).
   PubMedGoogle Scholar
• Karin M, Yamamoto Y, Wang QM. The IKK NF-κ B system: a treasure trove for drug development. Nat. Rev. Drug Discov.3(1), 17–26 (2004).
   PubMed Web of Science ®Google Scholar
• Moncada S, Vane JR. Prostacyclin: its biosynthesis, actions and clinical potential. Philos. Trans. R. Soc. Lond. B Biol. Sci.294(1072), 305–329 (1981).
   PubMed Web of Science ®Google Scholar
• Honn KV, Cicone B, Skoff A. Prostacyclin: a potent antimetastatic agent. Science212(4500), 1270–1272 (1981).
   PubMed Web of Science ®Google Scholar
• Lim HJ, Moon I, Han K. Transcriptional cofactors exhibit differential preference toward peroxisome proliferator-activated receptors α and δ in uterine cells. Endocrinology145(6), 2886–2895 (2004).
   PubMed Web of Science ®Google Scholar
• Fukumoto K, Yano Y, Virgona N et al. Peroxisome proliferator-activated receptor δ as a molecular target to regulate lung cancer cell growth. FEBS Lett.579(17), 3829–3836 (2005).
   PubMed Web of Science ®Google Scholar
• Malkinson AM. Role of inflammation in mouse lung tumorigenesis: a review. Exp. Lung Res.31(1), 57–82 (2005).
   PubMed Web of Science ®Google Scholar
• Dwyer-Nield LD, Srebernak MC, Barrett BS et al. Cytokines differentially regulate the synthesis of prostanoid and nitric oxide mediators in tumorigenic versus non-tumorigenic mouse lung epithelial cell lines. Carcinogenesis26(7), 1196–1206 (2005).
   PubMed Web of Science ®Google Scholar
• Malkinson AM, Beer DS. Major effect on susceptibility to urethan-induced pulmonary adenoma by a single gene in BALB/cBy mice. J. Natl Cancer Inst.70(5), 931–936 (1983).
   PubMed Web of Science ®Google Scholar
• Malkinson AM, Koski KM, Evans WA, Festing MF. Butylated hydroxytoluene exposure is necessary to induce lung tumors in BALB mice treated with 3-methylcholanthrene. Cancer Res.57(14), 2832–2834 (1997).
   PubMed Web of Science ®Google Scholar
• Duperron C, Castonguay A. Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carcinogenesis18(5), 1001–1006 (1997).
   PubMed Web of Science ®Google Scholar
• Rioux N, Castonguay A. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res.58(23), 5354–5360 (1998).
   PubMed Web of Science ®Google Scholar
• Ermert L, Dierkes C, Ermert M. Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors. Clin. Cancer Res.9(5), 1604–1610 (2003).
   PubMed Web of Science ®Google Scholar
• Stearman RS, Grady MC, Nana-Sinkam P, Varella-Garcia M, Geraci MW. Genetic and epigenetic regulation of the human prostacyclin synthase promoter in lung cancer cell lines. Mol. Cancer Res.5(3), 295–308 (2007).
   PubMed Web of Science ®Google Scholar
• Vane JR, Botting RM. Pharmacodynamic profile of prostacyclin. Am. J. Cardiol.75(3), 3A–10A (1995).
   PubMed Web of Science ®Google Scholar
• Komarova EA, Krivokrysenko V, Wang K et al. p53 is a suppressor of inflammatory response in mice. FASEB J.19(8), 1030–1032 (2005).
   PubMed Web of Science ®Google Scholar
• Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene18(49), 6938–6947 (1999).
   PubMed Web of Science ®Google Scholar
• Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell6(5), 447–458 (2004).
   PubMed Web of Science ®Google Scholar
• Pold M, Zhu LX, Sharma S et al. Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer. Cancer Res.64(5), 1853–1860 (2004).
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell100(1), 57–70 (2000).
   PubMed Web of Science ®Google Scholar
• Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest.117(5), 1175–1183 (2007).
   PubMed Web of Science ®Google Scholar
• Clevers H. At the crossroads of inflammation and cancer. Cell118(6), 671–674 (2004).
   PubMed Web of Science ®Google Scholar
• Spira A, Beane JE, Shah V et al. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat. Med.13(3), 361–366 (2007).
   PubMed Web of Science ®Google Scholar
• Seike M, Yanaihara N, Bowman ED et al. Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J. Natl Cancer Inst.99(16), 1257–1269 (2007).
   PubMedGoogle Scholar
• Lilenbaum R, Socinski MA, Altorki NK et al. Randomized Phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer. J. Clin. Oncol.24(30), 4825–4832 (2006).
   PubMed Web of Science ®Google Scholar
• Kummar S, Kinders R, Rubinstein L et al. Compressing drug development timelines in oncology using Phase ‘0’ trials. Nat. Rev. Cancer7(2), 131–139 (2007).
   PubMed Web of Science ®Google Scholar
• Mao JT, Fishbein MC, Adams B et al. Celecoxib decreases Ki-67 proliferative index in active smokers. Clin. Cancer Res.12(1), 314–320 (2006).
   PubMed Web of Science ®Google Scholar
• Mao JT, Cui X, Reckamp K et al. Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer. Clin. Lung Cancer7(1), 30–39 (2005).
   PubMed Web of Science ®Google Scholar
• Lee JM, Mao JT, Krysan K, Dubinett SM. Significance of cyclooxygenase-2 in prognosis, targeted therapy and chemoprevention of NSCLC. Future Oncol.3(2), 149–153 (2007).
   PubMedGoogle Scholar
• Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell4(6), 431–436 (2003).
   PubMed Web of Science ®Google Scholar